Red Biotechnology Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of Chronic Diseases And Rise In R&D Investments


Red Biotechnology Market


Red biotechnology refers to the application of biotechnology in human and animal healthcare. It involves production of therapeutics, diagnostics, regenerative medicines, biomaterials, medical devices, and other products used for treatment or prevention of diseases in humans or animals. Red biotechnology utilizes cell and tissue culture, bioinformatics, molecular tagging, DNA sequencing and genetic engineering to develop diagnostics tests, therapeutics, monoclonal antibodies, recombinant proteins, blood and vaccines.


Market Dynamics:
Red biotechnology market is primarily driven by increasing prevalence of chronic diseases globally. According to World Health Organization (WHO), chronic diseases accounted for approximately 70% of all deaths worldwide in 2020, equivalent to 41 million deaths annually. Cancer, cardiovascular diseases, diabetes, chronic respiratory diseases, and other noncommunicable diseases collectively are responsible for huge healthcare costs and reduced productivity. Rising geriatric population susceptible to age-related conditions also contributes to the market growth. According to UN estimates, the population aged 65 years and above is projected to grow from 703 million in 2019 to 1.5 billion in 2050.

Another key driver is increasing R&D investments in development of novel biologics and biosimilars. Biopharmaceutical companies are investing heavily in research of targeted therapies, antibody drug conjugates, cell and gene therapies to develop advanced treatment options. For instance, Amgen invested over US$ 4.5 billion in R&D in 2021 focusing on oncology, inflammation, cardiovascular,
Segment Analysis

The red biotechnology market is dominated by biopharmaceuticals segment. Biopharmaceuticals include therapeutic drugs and vaccines that are manufactured using biological sources like microbes, plants, animals and genetic engineering. This segment holds the largest share owing to increasing prevalence of chronic diseases and growing demand for advanced biologics and monoclonal antibody drugs for treating cancer, diabetes, cardiovascular diseases and other indications.

PEST Analysis

Political: Government regulations and funding for research promote growth of red biotechnology. Economic: Rising healthcare spending and increasing demand for low-cost biologics drive market growth. Social: Growing awareness about benefits of biologics and stem cell therapies fuel adoption. Technological: Advancements in genetic engineering, protein therapeutics and development of biosimilars support market expansion.

Key Takeaways

Global Red Biotechnology Market Demand is expected to grow from US$ 742.80 billion in 2023 to US$ 1.3 trillion by 2030, exhibiting a CAGR of 10.7% over the forecast period. The biopharmaceuticals segment dominates owing to high demand for therapeutic drugs and monoclonal antibodies. Regionally, North America holds the largest share due to presence of major players and technological advancements. However, Asia Pacific is emerging as the fastest growing market due to increasing R&D spending and strengthening healthcare infrastructure.

Key players operating in the red biotechnology market are Amgen, Gilead Sciences, Biogen, Pfizer, Novartis, Roche, Johnson & Johnson, Sanofi, Merck & Co., AbbVie, GlaxoSmithKline, AstraZeneca, Eli Lilly, Novo Nordisk, Bayer, Bristol-Myers Squibb, Teva Pharmaceutical, Takeda Pharmaceutical, Boehringer Ingelheim, Astellas Pharma. These players are focusing on developing innovative therapies and biosimilars through collaborations and acquisitions. 

Comments

Popular posts from this blog

Forging has significant application in creation of various metal for wide range of applications

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19

Ginseng Market Outlook, Analysis and forecast up to 2028